Assessment of alpha-galactosylceramide as a novel adjuvant for pandemic influenza: A virua vaccine [ 2006 - 2007 ]

Research Grant

Researchers: Prof Stephen Turner (Principal investigator) ,  Dr Ian Barr ,  Prof Dale Godfrey

Brief description The occurrence of human infections with pathogenic avian H5N1 Influenza A viruses was the first documentation of these viruses demonstrating an ability to directly transmit from birds to humans. The virulent nature of these infections, and the fact that there is no pre-existing immunity to these viruses in the human population has raised the concern that these viruses may emerge to cause the next influenza pandemic. Vaccination is our most effective way of protecting against influenza infection, however there are no commercially available avian influenza vaccines available. Moreover, recent evidence suggests current vaccines strategies may be less than effective. This proposal aims to evaluate the efficacy of a novel vaccine strategy that promotes immune protection against a potential pandemic influenza strain.

Funding Amount $AUD 220,042.09

Funding Scheme NHMRC Strategic Awards

Notes Urgent Research - Pandemic Influenza - H5N1